Illumina, Inc. offers genetic and genomic analysis solutions globally through Core Illumina and GRAIL segments. The company provides sequencing and array-based instruments, consumables, and services including whole-genome sequencing, genotyping, and noninvasive prenatal testing. It also develops solutions for cancer diagnoses and minimal residual disease detection. Illumina serves research centers, academic institutions, hospitals, pharmaceutical companies, and consumer genomics firms. Products are marketed directly to customers and through life-science distributors.
| Indicator | Value |
|---|---|
| PER | 100.0 |
| EV/EBITDA | 26.5 |
| Price/Free Cash Flow' | 24.4 |
| ROIC | 16.8% |
| Net Debt/EBITDA | 2.1 |